(19)
(11) EP 4 739 775 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24840368.5

(22) Date of filing: 08.07.2024
(51) International Patent Classification (IPC): 
C12N 9/24(2006.01)
C12N 15/52(2006.01)
A61P 31/12(2006.01)
 C07K 19/00(2006.01)
C12N 15/62(2006.01)
A61P 37/06(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 31/12; A61P 37/06; C12N 9/2402; C12Y 302/01096
(86) International application number:
PCT/US2024/037022
(87) International publication number:
WO 2025/014862 (16.01.2025 Gazette 2025/03)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 07.07.2023 US 202363525476 P
22.09.2023 US 202363584527 P

(71) Applicants:
  • Emory University
    Atlanta, Georgia 30322 (US)
  • The Rockefeller University
    New York, NY 10065 (US)

(72) Inventors:
  • SUNDBERG, Eric
    Atlanta, Georgia 30322 (US)
  • SASTRE, Diego
    Atlanta, Georgia 30322 (US)
  • DU, Jonathan
    Atlanta, Georgia 30322 (US)
  • BOURNAZOS, Stylianos
    New York, New York 10065 (US)
  • RAVETCH, Jeffrey V.
    New York, New York 10065 (US)

(74) Representative: Regimbeau 
20, rue de Chazelles
75847 Paris Cedex 17
75847 Paris Cedex 17 (FR)

   


(54) RECOMBINANT GLYCOSIDASES, PHARMACEUTICAL COMPOSITIONS, AND USES IN MANAGING AUTOIMMUNE OR INFLAMMATORY CONDITIONS